|Awarded On||February 21, 2018|
|Title||Characterizing cancer genome instability and translational impact using new sequencing technologies|
|Award Mechanism||Individual Investigator Research Awards for Computational Biology|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Ken Chen|
|Cancer Sites||All Sites|
Genome instability is a hallmark of cancer. Cancer cells with homologous recombination deficiency (HRD) often exibit a high level of chromosomal instability containing relatively large numbers of structural variations (SVs). Patients with homologous recombination deficiency (HRD) tumors have been shown to respond to Poly (ADP-ribose) polymerase (PARP) inhibitors. Meanwhile, cancer cells with mismatch-repair (MMR) deficiency often have high mutation (indel) burdens. Patients with MMR deficient tumors (e.g., melanoma and lung cancers) have demonstrated durable clinical responses to cancer immunotherapy such as CTLA-4 or PD-1/PD-L1 blockade. Still, a large fraction of patients were not benefit...